Sumaira Macdonald - Silk Road Chief Medical Officer
| SILK Stock | USD 18.90 1.10 6.18% |
Executive
Dr. Sumaira Macdonald is the Chief Medical Officer of the Company. rior to joining Silk Road Medical Inc., Dr. Macdonald was a Vascular Radiologist and Honorary Clinical Senior Lecturer at Newcastle University and the Freeman Hospital, Newcastle upon Tyne, UK
| Professional Marks | Ph.D |
| Address | 1213 Innsbruck Drive, Sunnyvale, CA, United States, 94089 |
| Phone | 408 720 9002 |
| Web | https://silkroadmed.com |
Silk Road Management Efficiency
The company has return on total asset (ROA) of (0.1385) % which means that it has lost $0.1385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3539) %, meaning that it created substantial loss on money invested by shareholders. Silk Road's management efficiency ratios could be used to measure how well Silk Road manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.22. The value of Return On Capital Employed is expected to slide to -0.26. The value of Total Current Liabilities is estimated to slide to about 20.6 M. The value of Liabilities And Stockholders Equity is expected to slide to about 171.6 MSimilar Executives
| Showing other executives | EXECUTIVE Age | ||
| Frank CFA | HCA Holdings | N/A | |
| Chen Zhang | Aesthetic Medical Intl | N/A | |
| Laura Groschen | Acadia Healthcare | N/A | |
| Joseph III | HCA Holdings | 67 | |
| Kirk Cheney | Pennant Group | N/A | |
| Jeffrey Cohen | HCA Holdings | 52 | |
| Nasser MD | Acadia Healthcare | N/A | |
| Isa Diaz | Acadia Healthcare | N/A | |
| Klara Radulyne | Novo Integrated Sciences | 38 | |
| Lyn Ketelsen | HCA Holdings | N/A | |
| Bill Priest | Acadia Healthcare | N/A | |
| Michael Marks | HCA Holdings | 53 | |
| Heather CPA | Acadia Healthcare | 52 | |
| Gretchen Hommrich | Acadia Healthcare | N/A | |
| Terence Arkel | HCA Holdings | N/A | |
| Mark Palmenter | Acadia Healthcare | N/A | |
| Emily Mattacchione | Novo Integrated Sciences | 43 | |
| Jim Brown | HCA Holdings | N/A | |
| MD MBA | HCA Holdings | 58 | |
| Qing Hu | Aesthetic Medical Intl | 60 | |
| Kathleen JD | HCA Holdings | 60 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.14 |
Silk Road Medical Leadership Team
Elected by the shareholders, the Silk Road's board of directors comprises two types of representatives: Silk Road inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Silk. The board's role is to monitor Silk Road's management team and ensure that shareholders' interests are well served. Silk Road's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Silk Road's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erica Rogers, President CEO, Director | ||
| Sumaira Macdonald, Chief Medical Officer | ||
| Mhairi Jones, VP Accounting | ||
| Sumaira MD, Executive Director | ||
| Kevin Ballinger, Chief Sec | ||
| Tammy Leitsinger, Compliance Affairs | ||
| Kevin Klemz, Chief EVP | ||
| Alison Highlander, Vice Resources | ||
| Jorge OHara, Business Marketing | ||
| Mark Caires, Vice President - Finance & Administration | ||
| Charles McKhann, Chief Officer | ||
| Richard Ruedy, Executive Vice President - Regulatory Affairs, Clinical Affairs & Quality Assurance | ||
| Lucas Buchanan, CFO COO | ||
| Lynn Lewis, Investors Officer | ||
| Andrew Davis, Chief Officer | ||
| Matthew McCarthy, Vice Marketing |
Silk Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Silk Road a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.30) % | ||||
| Current Valuation | 600.47 M | ||||
| Shares Outstanding | 39.17 M | ||||
| Shares Owned By Insiders | 5.93 % | ||||
| Shares Owned By Institutions | 94.07 % | ||||
| Number Of Shares Shorted | 4.14 M | ||||
| Price To Book | 4.71 X |
Currently Active Assets on Macroaxis
When determining whether Silk Road Medical is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Silk Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Silk Road Medical Stock. Highlighted below are key reports to facilitate an investment decision about Silk Road Medical Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Silk Road Medical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Silk Stock analysis
When running Silk Road's price analysis, check to measure Silk Road's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Silk Road is operating at the current time. Most of Silk Road's value examination focuses on studying past and present price action to predict the probability of Silk Road's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Silk Road's price. Additionally, you may evaluate how the addition of Silk Road to your portfolios can decrease your overall portfolio volatility.
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Silk Road's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Silk Road. If investors know Silk will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Silk Road listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.44) | Revenue Per Share 4.565 | Quarterly Revenue Growth 0.18 | Return On Assets (0.14) | Return On Equity (0.35) |
The market value of Silk Road Medical is measured differently than its book value, which is the value of Silk that is recorded on the company's balance sheet. Investors also form their own opinion of Silk Road's value that differs from its market value or its book value, called intrinsic value, which is Silk Road's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Silk Road's market value can be influenced by many factors that don't directly affect Silk Road's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Silk Road's value and its price as these two are different measures arrived at by different means. Investors typically determine if Silk Road is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Silk Road's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.